Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858793 | 1.00 | ABCB11 (0.44) | ABCB11TRPA1CYP1A2ALOX5PYCR1 | |
| SCHEMBL5878306 | 1.00 | ABCB11 (0.44) | ABCB11TRPA1CYP1A2ALOX5PYCR1 | |
| SCHEMBL2641075 | 0.87 | ABCB11 (0.52) | ABCB11TRPA1ESR1ESR2 | |
| SCHEMBL4493935 | 0.83 | TRPA1 (0.66) | TRPA1CYP1A2ALOX5PYCR1HTR2A | |
| SCHEMBL502172 | 0.82 | TRPA1 (0.46) | TRPA1CYP1A2ALOX5PYCR1HTR2A | |
| SCHEMBL6933308 | 0.80 | ABCB11 (0.47) | ABCB11TRPA1ESR1ESR2 | |
| SCHEMBL10396707 | 0.80 | ABCB11 (0.47) | ABCB11TRPA1ESR1ESR2SMN1; SMN2 | |
| SCHEMBL10396706 | 0.80 | ABCB11 (0.47) | ABCB11TRPA1ESR1ESR2SMN1; SMN2 | |
| SCHEMBL9694221 | 0.80 | ABCB11 (0.47) | ABCB11TRPA1ESR1ESR2 | |
| SCHEMBL17946512 | 0.80 | ALOX5 (0.39) | TRPA1CYP1A2ALOX5PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064328-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| US-9663515-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| US-8497271-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-30 | — | — | US | disclosed |
| US-8420830-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420830-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-06 | — | — | US | disclosed |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6521605-B1 | Potentiating glutamate receptor function; treating such as psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| CN-1251523-A | Sulfonamide derivatives | LILLY CO ELI (US) | 2000-04-26 | — | — | CN | disclosed |
| WO-2000006176-A1 | AMIDOPHOSPHATE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006156-A1 | AMIDE, CARBAMATE, AND UREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | ABCB11 1791/4885TRPA1 313/4885CYP1A2 2144/4885 |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | ABCB11 566/4885TRPA1 609/4885CYP1A2 128/4885 |
| US-20100113488-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F5 | ABCB11 825/4885TRPA1 4683/4885CYP1A2 558/4885 |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | ABCB11 3857/4885TRPA1 2480/4885CYP1A2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.